Nachrichten zur Sarepta Therapeutics Aktie

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year,…

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The companys…

Sarepta Therapeutics Aktie: Elevidys weiter vielversprechend, aber Analysten bleiben vorsichtig

Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Scotiabank: Rating und Kursziel Scotiabank senkt das Kursziel für die Aktie von Sarepta Therapeutics Inc. (ISIN:…

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?

Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest…

Sarepta Therapeutics faces new safety concerns for gene therapy ELEVIDYS following patient death

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has…

Sarepta Therapeutics faces new safety concerns following patient death

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has…

Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript

…

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript

SRPT earnings call for the period ending December 31, 2024.…

Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -19.79% and 2.83%, respectively, for the quarter ended December 2024. Do…

Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Heres Why You Should Buy the Stock Now

Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This…

Down -8.52% in 4 Weeks, Heres Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In…

2 Growth Stocks to Buy Hand Over Fist in February

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in…

Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

…

Sarepta Therapeutics SWOT analysis: DMD leaders stock poised for growth By Investing.com

Sarepta Therapeutics SWOT analysis: DMD leaders stock poised for growth…

Sarepta Therapeutics Aktie: Zusammenarbeit mit Arrowhead strategisch wertvoll

Minneapolis (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Piper Sandler: 1. Neue Bewertung und Kurszielsetzung Piper Sandler hat das Kursziel für die Aktie von…

Sarepta Therapeutics Aktie: siRNA-Technologie gesichert - Neue Chancen für das neuromuskuläre Portfolio

Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von BMO Capital Markets: Aktuelle Bewertung Die Analysten von BMO Capital Markets stufen die Aktie von Sarepta…

Sarepta Therapeutics Aktie: Pipeline-Stärkung durch neuen Lizenzdeal

Charlotte (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von BofA Securities: Rating und Kursziel BofA hat das Kursziel für die Aktie von Sarepta Therapeutics Inc.…

Sarepta Therapeutics Aktie: Partnerschaft mit Arrowhead ist ein kluger Schachzug

Boston, MA (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Leerink Partners: Aktuelle Bewertung Die Analysten von Leerink Partners stufen die Aktie von Sarepta Therapeutics…

Sarepta Therapeutics Aktie: Attraktive Kaufgelegenheit

New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von J.P. Morgan Securities: JPMorgan sieht die jüngste Schwäche der Aktie von Sarepta Therapeutics Inc.…

Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step

…

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript

SRPT earnings call for the period ending September 30, 2024.…

Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript

…

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics

These two could become direct competitors relatively soon.…

Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript

SRPT earnings call for the period ending June 30, 2024.…

Sarepta Therapeutics falls on revenue miss, weak outlook By Investing.com

Sarepta Therapeutics falls on revenue miss, weak outlook…

Is Pfizers Pain Sarepta Therapeutics Gain? Dont Bet on It.

One companys negative results can increase scrutiny of anothers work.…

Sarepta Therapeutics: Herabstufung nach der 30-prozentigen Rally - Aktienanalyse

New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von der Citigroup: Die Analysten der Citigroup stufen die Aktie des Biopharma-Unternehmens Sarepta Therapeutics Inc.…

Sarepta Therapeutics: Kurszielanhebung

New York (www.aktiencheck.de) - Rating-Update: Gavin Clark-Gartner, Analyst von Evercore ISI, stuft die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…

Sarepta Therapeutics: Kursziel verbessert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Morgan Stanley stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…

Sarepta Therapeutics: Annahmen aktualisiert - Aktienanalyse

Boston, MA (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Leerink Partners: Die Analysten von Leerink Partners erhöhen in einer aktuellen Aktienanalyse ihr Kursziel…

Sarepta Therapeutics: Kursziel gesteigert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Goldman Sachs bewerten die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…

Sarepta Therapeutics: Monopol in Verbindung mit Bedarf bei DMD biete kommerzielle Chance - Aktienanalyse

Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von BMO Capital Markets: Die Analysten von BMO Capital Markets erhöhen in einer aktuellen Aktienanalyse ihr…

Sarepta Therapeutics: Kursziel angehoben

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Needham & Co stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…

Sarepta Therapeutics: Kurszielerhöhung

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten vom Investmenthaus RBC Capital Markets stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…

Sarepta Therapeutics (SRPT) Soars 30.1%: Is Further Upside Left in the Stock?

Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

Sarepta Therapeutics: Kursziel hochgesetzt

Charlotte (www.aktiencheck.de) - Rating-Update: Tazeen Ahmad, Analyst von BofA Securities, stuft die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH,…

Sarepta Therapeutics: Pushing The Edge And Creating The Horizon

…

Sarepta Therapeutics: Why Todays Rally On DMD Drug Label Expansion Wont Last

…

Stocks making the biggest moves midday: Sarepta Therapeutics, Hertz Global, Asana and more

These are the stocks posting the largest moves in midday trading.…

Sarepta Therapeutics shares surge as muscular dystrophy therapy approved for expanded use

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use…

Sarepta Therapeutics shares surge on expanded approval of muscular dystrophy therapy

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares soared almost 35% after the US Food and Drug Administration (FDA) approved the expanded use…

Sarepta Therapeutics legt nach FDA-Zulassung stark zu - Aktiennews

Frankfurt (www.aktiencheck.de) - Sarepta Therapeutics legt nach FDA-Zulassung stark zu - Aktiennews Sarepta Therapeutics (ISIN: US8036071004, WKN: A1J1BH, Ticker-Symbol: AB3A, NASDAQ-Symbol:…

Stocks making the biggest moves premarket: Gilead Sciences, Sarepta Therapeutics, Nike and more

These are the stocks posting the largest moves in premarket trading.…

Roche-Partner Sarepta Therapeutics-Aktie zündet Turbo nach FDA-Zulassung für Millionen-Dollar-Behandlung

• Sarepta Therapeutics erhält erweiterte FDA-Zulassung • Zusammenarbeit mit Roche bei Medikament gegen Muskelschwund • Sarepta Therapeutics-Aktie mit Kurssprung …

Market Rally Tries To Steady As AI Stocks Extend Losses

The Nasdaq and S&P 500 fell from record highs Thursday. Sarepta Therapeutics surged Friday on FDA approval.…

Top Stock Movers Now: FactSet, Sarepta Therapeutics, Spirit AeroSystems, and More

The Dow, S&P 500, and Nasdaq were little changed at midday Friday, June 21, 2024 as reports showed existing home…

Sarepta Therapeutics: Kräftiger Kurssprung nach Zulassungsneuigkeiten - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse vom Online-Anlegermagazin "Der Aktionär": Michel Doepke von "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die des…

Sarepta Therapeutics surges 36% after-hours following expanded FDA approval By Investing.com

Sarepta Therapeutics surges 36% after-hours following expanded FDA approval…

Sarepta Therapeutics: Navigating Elevidys Upside Potential

…